New treatment for nicotine addiction using e-vape technology.
Revolutionizing Nicotine Vaping and Electronic Nicotine Delivery Systems Addiction Treatment through Innovative E-Vape Administration of Cytisine to Enhance Patient Adherence and Treatment Completion.
['FUNDING_SBIR_1'] · SPACERX LLC · NIH-11008626
This study is testing a new way to help people quit smoking or vaping by using a medication called cytisine in e-vape devices, making it easier for those who have tried to quit before to stick with their treatment.
Quick facts
| Phase | ['FUNDING_SBIR_1'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SPACERX LLC (nih funded) |
| Locations | 1 site (RESTON, UNITED STATES) |
| Trial ID | NIH-11008626 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel treatment for nicotine addiction by using cytisine, a smoking cessation drug, administered through e-vape devices. The approach aims to enhance patient adherence and treatment completion by allowing individuals to self-administer the medication in a familiar format. The study targets those who have struggled with quitting smoking or vaping, particularly those who have made multiple unsuccessful attempts. By addressing both the physical and behavioral aspects of nicotine addiction, this research seeks to provide a more effective solution for cessation.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults and adolescents who are dependent on nicotine and have previously attempted to quit without success.
Not a fit: Patients who are not currently using nicotine products or those who have successfully quit smoking or vaping may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the success rates of individuals trying to quit nicotine by providing a more accessible and effective treatment option.
How similar studies have performed: While the use of cytisine for smoking cessation has been explored, this specific approach using e-vape technology is innovative and has not been widely tested.
Where this research is happening
RESTON, UNITED STATES
- SPACERX LLC — RESTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LEE, PETER H — SPACERX LLC
- Study coordinator: LEE, PETER H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.